Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availability of new and highly effective immunotherapeutic agents including immune checkpoint(s) blocking monoclonal antibodies, allows us to plan for highly innovative proof-of-principle combination studies that will likely open the path to more effective anticancer therapies. (C) 2015 Elsevier Inc. All rights reserved.
Covre, A., Coral, S., Di Giacomo, A.M., Taverna, P., Azab, M., Maio, M. (2015). Epigenetics meets immune checkpoints. SEMINARS IN ONCOLOGY, 42(3), 506-513 [10.1053/j.seminoncol.2015.02.003].
Epigenetics meets immune checkpoints
Covre A.;Di Giacomo A. M.;Maio M.
2015-01-01
Abstract
Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availability of new and highly effective immunotherapeutic agents including immune checkpoint(s) blocking monoclonal antibodies, allows us to plan for highly innovative proof-of-principle combination studies that will likely open the path to more effective anticancer therapies. (C) 2015 Elsevier Inc. All rights reserved.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Covre A, OncoImmunology 2015.pdf
non disponibili
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
598.45 kB
Formato
Adobe PDF
|
598.45 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1090111